Authors: Aguilar-Salinas, Carlos A.; Mehta, Roopa; Rojas, Rosalba; Gomez-Perez, Francisco J.; Olaiz, Gustavo; Rull, Juan A.

Source: Current Diabetes Reviews, Volume 1, Number 2, June 2005 , pp. 145-158(14)

Publisher: Bentham Science Publishers

Abstract:

The metabolic syndrome is known to increase cardiovascular morbidity and precede the development of type 2 diabetes. Even before the appearance of hyperglycemia, the components of the metabolic syndrome play a crucial role in the pathogenesis of the macrovascular complications. Thus, the recognition and treatment of the metabolic syndrome may be a strategy to prevent the most likely cause of death (i.e. cardiovascular events) in cases that eventually develop type 2 diabetes. In this review, controversial issues regarding the treatment of the two main components of the metabolic syndrome (i.e dyslipidemia and arterial hypertension) are discussed. Several disparities in the current NCEP-ATPIII recommendations, when applied to patients with the metabolic syndrome, are pointed out. In population-based studies, the number of individuals with the metabolic syndrome who would need LDL cholesterol lowering treatment following these guidelines is remarkably low compared to subjects belonging to the same risk strata (10 year risk 10-20%). Subjects with the metabolic syndrome do not fall into the same risk category, resulting in differing LDL-C targets. Also, the Framingham tables underestimate the cardiovascular risk associated with the metabolic syndrome; hence fewer cases qualify for drug therapy. In addition, LDL-C underestimates the number of atherogenic particles and is therefore not the ideal target for these patients. The selection of antihypertensive medication in the metabolic syndrome is also controversial. Thus, there is sufficient evidence for a review of the current management of the metabolic syndrome as part of a strategy to prevent the macrovascular complications in type 2 diabetes.

Keywords: dyslipidemia; national cholesterol education program; non-hdl cholesterol; apolipoprotein b; metabolic syndrome

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1573399054022767

Affiliations: 1: Vasco de Quiroga 15, Mexico City 14000, Mexico.

Publication date: 2005-06-01

More about this publication?

• Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy.
  
  The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine ,  Medicine (General)
• By this author: Aguilar-Salinas, Carlos A. ;  Mehta, Roopa ;  Rojas, Rosalba ;  Gomez-Perez, Francisco J. ;  Olaiz, Gustavo ;  Rull, Juan A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers